期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小剂量沙利度胺联合泼尼松治疗慢性特发性骨髓纤维化11例临床疗效观察 被引量：3

原文传递
导出
摘要 慢性特发性骨髓纤维化（cIMF）是一种病因未明的慢性骨髓增殖性疾病，典型的临床表现为进行性贫血，脾脏肿大，外周血出现幼稚红细胞、幼稚粒细胞、泪滴状红细胞以及不同程度的骨质硬化。骨髓穿刺常干抽，部分患者可进展为急性白血病，一般中位生存期5（1～20）年。异基因造血干细胞移植是根治骨髓纤维化的唯一方法，但因大多数患者年龄大、HIA配型困难及高额治疗费用而大大限制了其临床应用，因而，更多采用减轻症状、改善生存质量的非移植方法。
作者 尹延珂 王慧君 张莉 周康 李洪强 杨栋林 张凤奎
机构地区 中国医学科学院中国协和医科大学血液学研究所血液病医院
出处 《中华血液学杂志》 CAS CSCD 北大核心 2007年第11期766-767,共2页 Chinese Journal of Hematology
关键词 慢性骨髓增殖性疾病 特发性骨髓纤维化 临床表现 治疗费用 疗效观察 沙利度胺 异基因造血干细胞移植 泼尼松
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献8

  • 1张之南 忱悌.血液病诊断及疗效标准（第2版）[M].北京:科学出版社,1999.270-271.
  • 2Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol, 1994 ,88:9-16.
  • 3Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaroeytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol, 1997,97 : 441- 448.
  • 4Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood,2000,96:3374-3380.
  • 5Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol,2002 ,117 :288-296.
  • 6Mesa RA . Steensma DP,Pardanani A,et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood ,2003,101:2534-2541.
  • 7胡喜梅,周水阳,徐洪,张红,倪君,朱碧辉.沙利度胺治疗原发性骨髓纤维化临床疗效观察[J].中国药物与临床,2004,4(7):507-509. 被引量：3
  • 8Giovanni B, Michelle E, Letizia C, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma,2002,43:2301-2307.

二级参考文献9

  • 1[1]张之南,主编.血液病诊断及疗效标准.第2版.北京:科学出版社,1999.373-379.
  • 2[2]Mesa RA, Rajkumar SV, Hanson CA, et al. Evaluation and clinical correlation of microvessel density in myelofibrosis with myeloid metaplasia. Blood, 1999, 94(Suppl 1 ): 115a.
  • 3[3]Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakarocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol, 1997, 97(2):441-448.
  • 4[4]Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-13 and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol, 1994, 88(1):9-16.
  • 5[5]D'Amato RJ,Loughnan MS,Flynn E, et al. Thalidomide is an in hibitor of angiogenesis. Proc Natl Acad Sci USA, 1994, 91 (9):4082-4085.
  • 6[6]Giovanni B, Michelle E, Letizia C, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of indi vidual patient data from five studies.Leuk Lymphoma, 2002, 43(12):2301-2307.
  • 7[7]Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia: a pilot study. Leukemia, 2002, 16 (9):1609-1614.
  • 8[8]Elliott MA, Mesa RA,Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol, 2002, 117(2):288-296.
  • 9[9]Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treat ment of myelofibrosis with myeloid metaplasia. Blood, 2003, 101(7):2534-2541.

共引文献66

同被引文献24

  • 1莫汉有,蒋静子,覃泱,莫东华,周润华.原发性骨髓纤维化患者血管内皮生长因子水平变化与反应停的干预[J].中国临床康复,2006,10(33):59-61. 被引量：1
  • 2MARTYER M C,ROMQUIN N, LE BOUSSE-KERDILES M C, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis[J]. Br J Haematol, 1994,88 : 9 - 16.
  • 3BOCK O, LOCK G, BUSCHE G, et al. Aberrant expression of platelet-drived growth factor (PDGF)and latelet-drived growth factor receptor-alpha is associated with advanced bone marrow fibrosis in idiopathic myelofibrosis[J]. Haematol, 2005,90 : 133-134.
  • 4MESA R A,EILLIOLL M A,SCHROEDER G,et al. Durable response to thalidomide based drug therapy for myelofibrosis[J]. Mayo Clin Proc, 2004,79 : 883 - 889.
  • 5SPETS H, STROMBERG T, GEORGII HEMMING P,et al. Expression of the bcl-2 family of pro and anti apoptosis genes in multiple myeloma and normal plasma cells: regulation during interleukin 6 (IL- 6) induced growth and survival[J]. Eur J Haematol,2002, 69:76-89.
  • 6MESA R A, STEENSMA D P, PARDANANI A, et al. A phase 2 trial of combination low-dose Thalidomide and prednisone for the treatment of myelofibrosis with myeloed metaplasia[J]. Blood, 2003,101 : 2534 - 2541.
  • 7WU W Z,SUN H C,SHEN Y F,et al. Interferon alpha 2a down-regulates VEGF expression through P13 kinase and MAP kinase signaling pathways [J]. J Cancer Res Clin Oncol,2005,131 : 169- 178.
  • 8张海燕,李长龙.帕米磷酸二钠联合沙立度胺对平台期多发性骨髓瘤患者血清VEGF及IL-6的影响及临床意义[J].临床血液学杂志,2007,20(5):302-303. 被引量：1
  • 9Martyr e MC, le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haernatol, 1997,97(2) :441-448.
  • 10Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis inmyelofibrosis with myeloid metaplasia. Blood, 2000,96(10) : 3374-3380.

引证文献3

二级引证文献6

中华血液学杂志
2007年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部